Whalesbook
The Anchor Allocation and Market Context
Hexagon Nutrition’s anchor book garnered ₹41.65 crore from institutional participants on June 4, signaling modest interest ahead of the public issue. Bandhan Mutual Fund led the commitment with a ₹12 crore allocation, followed by Ampersand Growth Opportunities Fund and CP Capital. With the price band fixed at ₹42–₹45 per share, the company is seeking to command a pre-IPO market capitalization of approximately ₹553 crore. However, institutional appetite for this niche nutrition player remains tested by the broader volatility in the primary markets.
The Capitalization Paradox
Investors must distinguish between corporate growth and liquidity events. This IPO is structured as a 100% offer-for-sale (OFS), wherein the Kelkar family is divesting a significant portion of their holding. Because the company will not receive any proceeds from the issuance, the capital influx will not enhance manufacturing capacity, reduce debt, or fund R&D initiatives. Instead, it serves exclusively as an exit mechanism for existing shareholders. While the firm’s revenue trajectory has shown resilience—rising from ₹281 crore in FY23 to ₹331 crore in FY25—the absence of fresh equity limits the long-term thematic utility of the listing for the company itself.
The Forensic Bear Case
Beyond the headline growth numbers, several structural risks demand scrutiny. First, the company’s heavy reliance on large FMCG clients creates significant customer concentration risk, making revenue streams vulnerable to the procurement shifts of a few key entities. Second, the international exposure, while touted as a strength, carries geographical and currency-related volatility, particularly concerning operations in Uzbekistan. Third, observers have noted aggressive, and at times misleading, peer comparisons; attempting to position a company with a ₹553 crore market cap against industry giants like Nestlé or Zydus Wellness ignores fundamental differences in scale, balance sheet depth, and market dominance. Finally, the exit of several key family members via this OFS introduces concerns regarding the long-term commitment of the founding group to the company’s future governance.
Future Outlook
Market participants are weighing the company’s specialized position in the food fortification premix market against the premium valuation being sought. As the IPO opens for subscription from June 5 to June 9, the focus will shift to subscription levels across the Retail and Qualified Institutional Buyer (QIB) categories. While the niche nature of their micronutrient and clinical nutrition portfolio provides a degree of defensive utility, the lack of fresh capital infusion and the aggressive promoter exit strategy suggest that investors should prioritize the sustainability of margins and client retention rates over initial listing-day enthusiasm.